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Abstract 
 
Converging evidence from pharmacological investigations, genetic association studies 
and schizophrenia research indicates an important influence of the dopamine system 
on sensorimotor gating as measured by prepulse inhibition (PPI) of the acoustic startle 
response. In particular, D2 receptor agonists have been shown to disrupt PPI in 
humans and rodents. In the present study, we investigated the associations of two 
functional DRD2 related single nucleotide polymorphisms (rs4648317 and rs1800497, 
the latter also known as DRD2 / ANKK1 Taq1A) with PPI in two independent healthy 
human samples (overall N=197; Munich N=101; London N=96). Taq1A is a prominent 
marker of striatal D2 receptor signalling and was therefore hypothesized to impact on 
PPI. In line with our hypothesis, we report here reduced PPI levels in individuals with 
higher striatal D2 receptor signalling as indicated by the Taq1A genotype. Meta-
analysis across both samples confirmed this finding. In contrast, an association 
between rs4648317 and PPI found in the Munich sample could not be confirmed in the 
London sample. Overall, the present study helps to bridge the gap between 
pharmacological manipulations of PPI and molecular genetics of the dopaminergic 
system. 
 
Keywords: 
Prepulse Inhibition, Dopamine, Acoustic Startle Response, DRD2, Taq1a 
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1. Introduction 
Prepulse inhibition (PPI) of the acoustic startle response (ASR) is a widely used 
psychophysiological measure of sensorimotor gating (Braff et al., 1978, Geyer et al., 
1990, Swerdlow and Geyer, 1998) which helps to avoid sensory information overflow 
(Braff et al., 1999). In this paradigm, in humans first described by Krauter (1973) and 
systematically investigated by Graham (1975), a loud noise is used to produce a startle 
reflex that is commonly measured electromyographically above the Musculus 
orbicularis oculi as an eyeblink reflex. Graham (1975) found that a non-startling 
prestimulus preceding the startling stimulus by 30-500msec reduces the eyeblink reflex 
of human subjects. 
PPI is reduced in people with schizophrenia (e.g., Braff et al., 1978, Kumari et al., 
2008, Swerdlow et al., 2006), in unaffected first-degree relatives of schizophrenia 
patients (Cadenhead et al., 2000, Kumari et al., 2005b), in the prodromal stage of 
schizophrenia (Quednow et al., 2008) and in schizotypal personality disorder (SPD) 
(Cadenhead et al., 1993, Cadenhead et al., 2000). PPI is partially heritable (Anokhin et 
al., 2003, Dulawa and Geyer, 2000, Greenwood et al., 2007, Willott et al., 2003) with 
heritability estimates ranging from 32% to >50%. Together, these studies indicate that 
PPI may represent a schizophrenia endophenotype (Gottesman and Gould, 2003). 
The neural basis of PPI in rodents lies in the cortico-pallido-striatal-thalamic and 
pontine circuitry, with evidence for involvement of the prefrontal cortex, thalamus, 
hippocampus, nucleus accumbens (NAC), striatum, ventral pallidum (VP), globus 
pallidus, and subpallidal efferents to the pedunculopontine nucleus (PPTg) (review, 
Swerdlow et al., 2008). Functional (Campbell et al., 2007, Kumari et al., 2003, Kumari 
et al., 2007, Neuner et al., 2010) and structural (Kumari et al., 2005a) neuroimaging 
studies agree with involvement of these regions in human PPI. 
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Important clues in the ongoing investigation of the neural control of PPI come from 
pharmacological studies. Specifically, there is evidence for an important role of the D2 
dopamine receptor (DRD2). For example, it has been shown that DRD2-agonists in 
rats disrupt PPI (Peng et al., 1990, Swerdlow et al., 2002b). Furthermore, PPI deficits 
induced by apomorphine (a D1 and D2 receptor agonist) in rats can be reversed by 
haloperidol (which acts as a D2 antagonist) exhibiting a dose-response relation that is 
highly correlated with its antipsychotic potency in schizophrenia patients (Martinez et 
al., 2000, Swerdlow et al., 1994, Swerdlow and Geyer, 1993). These disruptive effects 
of D2 receptor agonists on PPI are presumably mediated by dopaminergic activity in 
the NAC (review, Swerdlow et al., 2001): increased dopaminergic signaling in the NAC 
is thought to reduce activity of GABAergic projections to the VP (Kretschmer and Koch, 
1998). VP activity, in turn, is assumed to cause a tonic regulation of the PPTg which is 
thought to mediate PPI via innervations of the nucleus reticularis pontis caudalis (PnC) 
(review, Fendt et al., 2001). Irrespective of NAC activity, the caudate nucleus also 
seems to play a role in the dopaminergic regulation of PPI (Hart et al., 1998). 
In contrast to rats, in humans the effects of D2 receptor agonists such as bromocriptine 
are less clear: whereas some studies found a disruptive effect of bromocriptine on PPI 
(Abduljawad et al., 1998, Abduljawad et al., 1999), others did not (Swerdlow et al., 
2002a, 2002b). 
Complementary to pharmacological manipulation studies, the investigation of functional 
genetic polymorphisms offers another way to elucidate the role of specific 
neurotransmitter systems in human PPI. An advantage of this approach is that naturally 
occurring variation in the expression level or functional properties of a protein is used 
without exogenous manipulations as in pharmacological investigations. Focusing on 
dopaminergic influences on sensorimotor gating such studies have established 
associations between a number of genetic polymorphisms and PPI. Among the most 
prominent single nucleotide polymorphisms (SNP) showing association with PPI are 
the catechol-O-methyltransferase (COMT) Val158Met SNP (Quednow et al., 2009, 
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2010, Roussos et al., 2008b), and the dopamine-receptor D3 (DRD3) Ser9Gly SNP 
(Roussos et al., 2008a). These molecular genetic findings strengthen the evidence for 
a modulatory role of dopamine in PPI. 
Accordingly, in order to further probe the role of the D2 receptor in PPI, some previous 
studies have examined associations of PPI with SNPs in the D2 dopamine receptor 
(DRD2) gene (Hokyo et al., 2010, Montag et al., 2008, Roussos et al., 2008b). Hokyo 
and colleagues (2010) investigated interaction effects between Japanese 
schizophrenia patients and healthy controls on the association between PPI and DRD2 
rs1801028 and rs6277, respectively. Montag at al. (2008) and Roussos et al. (2008b) 
examined the DRD2/ANKK1 Taq1A (rs1800497) SNP in healthy, Caucasian subjects. 
None of these studies obtained a significant association between the DRD2 SNPs and 
PPI. However, the two studies of the DRD2/ANKK1 Taq1A SNP (Montag at al. 2008, 
Roussos et al. 2008b), a polymorphism widely studied in the context of striatal 
dopamine signaling, used somewhat uncommon startle parameters and experimental 
variations of prepulse intensity, respectively. Importantly, small changes in stimulus 
characteristics can considerably affect PPI (e.g., Csomor et al., 2006, 2008, Hsieh et 
al., 2006). Therefore, the generalisability of those initial DRD2/ANKK1 Taq1A SNP 
findings is limited. Additionally, Montag et al. (2008) sampled only female subjects, 
whereas Roussos (2008b) included only male subjects. 
Given the role of the DRD2/ANKK1 Taq1A SNP in striatal dopamine signaling 
(Hirvonen et al., 2009, Jönsson et al., 1999, Pohjalainen et al., 1998a, Ritchie and 
Noble, 2003, Thompson et al., 1997), it is important to further examine this matter 
using established stimulus characteristics with known sensitivity to schizophrenia 
(Kumari and Ettinger, 2005). The present study therefore aims to clarify the influence of 
D2 receptor signalling on sensorimotor gating by investigating associations of DRD2 
SNPs with PPI. Specifically, two functional DRD2 related SNPs, rs7122454/rs4648317 
and rs1800497 (DRD2/ANKK1 Taq1A), are examined.  
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The DRD2/ANKK1 Taq1A polymorphism is located 9.5kb downstream from the DRD2 
gene (Grandy et al., 1993) in the ankyrin repeat and kinase domain containing 1 
(ANKK1) gene. The ANKK1 and DRD2 genes overlap and share haplotype blocks. The 
Taq1A SNP leads to a substitution of an acidic amino acid for a basic amino acid 
(Glu713Lys) which potentially might lead to a change in protein function. The mutated 
A1 allele has a prevalence of 19.5%, the homozygous A1A1 genotype of 5.3% in 
healthy humans of Caucasian descent (The International HapMap Consortium, 2003). 
Therefore, the A1 allele carriers are often contrasted with carriers without the A1 allele, 
i.e. A2 allele homozygotes. Crucially, several positron emission tomography and 
autoradiographic studies have shown that the minor A1 allele is associated with 
reduced striatal D2 receptor density (up to 30%) and receptor binding compared to the 
A2A2 allele status in humans (Hirvonen et al., 2009, Jönsson et al., 1999, Pohjalainen 
et al., 1998a, Ritchie and Noble, 2003, Thompson et al., 1997). In addition, the A1 
allele has been associated with reduced substantia nigra volume (Cerasa et al., 2009), 
a key dopaminergic area. The role of the Taq1A polymorphism in the aetiology of 
schizophrenia is controversial: whereas some case-control studies found an 
association of the A1 allele with schizophrenia (Comings et al., 1991, Monakhov et al., 
2008), other studies provided evidence for an increased frequency of the A2 allele in 
schizophrenia patients (Dubertret et al., 2001, 2004, 2010, Vijayan et al., 2007). 
Golimbet et al. (2003) found that schizophrenia-concordant sibling pairs had 
significantly more often common alleles at the Taq1A locus.  
The second SNP investigated in this study is rs4648317/rs7122454, two SNPs in 
complete linkage disequilibrium (LD). This SNP (unlike Taq1A) has been associated in 
females with prolactin concentrations (Fukui et al., 2010). Prolactin secretion is 
inhibited by the hypothalamic dopamine transmission via the D2 receptor (Grattan and 
Kokay, 2008). Specifically, the T allele was associated with increased prolactin 
concentration presumably caused by a reduced D2 receptor transmission. This SNP is 
located in intron 1 of DRD2 and alters two potential transcription factor binding sites 
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(Laucht et al., 2008) which might indicate an effect on DRD2 expression. Laucht and 
colleagues (2008) also reported an association between rs4648317 and nicotine 
dependence in adolescents, with the T allele carrier status related to higher nicotine 
dependence. As nicotine causes striatal dopamine release in rats (e.g. Kaiser et al., 
1998, Wonnacott et al., 2000) and in humans (Brody et al., 2004), Laucht et al. (2008) 
suggested that the association between DRD2 SNPs and nicotine dependence might 
rely on changes in striatal DRD2 expression levels that influence, in turn, nicotine-
induced reward mediated by dopamine release. If this is true, we would also expect an 
association of this SNP with PPI. 
In addition, Hamidovic and colleagues (2009) found an association between rs4648317 
genotype and inhibitory performance in the stop signal task as well as self-report 
impulsivity (Zuckerman–Kuhlman Personality Questionnaire, Impulsivity subscale). 
Both measures indicated lower impulsivity of T allele carriers compared to CC carriers. 
In summary, we investigated the association with PPI of two DRD2 SNPs thought to 
influence striatal dopamine signalling. Given the importance of replication in molecular 
genetics (Chanock et al., 2007) we investigate this relationship in two independent 
samples. Based on previous molecular studies, we hypothesized that Taq1A A2A2 
allele carriers, who exhibit higher striatal DRD2 levels compared to A1 carriers, would 
show reduced PPI. Considering rs4648317/rs7122454, we had no directed hypothesis. 
However, based on previous research on nicotine dependence we expected an 
association between this SNP and PPI. 
 
2. Methods and Materials 
2.1 Participants 
2.1.1 Munich sample 
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One hundred eighteen healthy unrelated volunteers of Caucasian descent were 
recruited through local advertisements in Munich, Germany. Exclusion criteria 
consisted of (1) any current psychiatric diagnosis (using the German version of the 
Mini-International Neuropsychiatric Interview; Ackenheil et al., 1999), (2) a history of 
neurological complications, (3) a history of psychosis or attention deficit hyperactivity 
disorder in first-degree relatives, (4) any current physical condition, (5) any current 
consumption of over-the-counter or prescription medication (except for contraceptives), 
and (6) any hearing impairments or tinnitus. Participants provided demographic 
information and data on smoking status and severity (using the Fagerström test for 
nicotine dependence; Heatherton et al., 1991). Subjects scoring >0 on this test were 
considered smokers. 
 
2.1.2 London sample 
One hundred and six healthy Caucasian volunteers were recruited through local 
advertisements in South London, UK. Exclusion criteria consisted of (1) DSM-IV Axis I 
disorders using the Structured Clinical Interview for DSM-IV Disorders for healthy 
subjects (SCID-NP), (2) a history of neurological complications, substance abuse or 
dependence, or hearing impairments, (3) a history of psychosis in first-degree relatives, 
and (4) any current physical condition or medication. The assessment of smoking 
behaviour was identical to the Munich sample.  
 
For both samples, the study had approval by the local ethics committees. Subjects 
provided written informed consent and were reimbursed for their participation. 
 
2.2 Genotyping 
For the Munich sample DNA was extracted from 3 ml saliva samples using QIAamp 
DNA-Blood-Midi-Kit (QIAGEN, Germany). For the London sample DNA was extracted 
from cheek swabs or venous blood. Genotyping was based on MALDI- (Matrix Assisted 
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Laser Desorption/Ionisation) TOF (time of flight) mass spectrometry (Haff and Smirnov, 
1997). Therefore, genomic sequences flanking the SNPs of interest of the extracted 
DNA samples were first amplified using a Multiplex polymerase chain reaction (PCR), 
otherwise called SNP Capture reaction (Oeth et al., 2005). The primers for the 
Multiplex PCR were as follows: for ANKK1 Taq1A (rs1800497) the forward primer: 5’-
XTG TGC AGC TCA CTC CAT CCT-3’ and the reverse primer: 5’-XTC AAG GGC AAC 
ACA GCC ATC-3’; for DRD2 rs7122454 the forward primer: 5’-XTA AAA TGG TGG 
TGG CCA GAG-3’ and the reverse primer: 5’-XGT CTT GAA ACA CTG AAG CTC-3’ 
(X=ACGTTGGATG; mass tag). 
MassExtend-primers that were hybridizing at the 5’ end directly in front of the 
polymorphic locus of the PCR products were used for genotyping. These MassExtend-
primers (including possible extensions) were as follows: for ANKK1 Taq1A 
(rs1800497): 5’-CAT CCT CAA AGT GCT GGT C(A/G)-3’; for DRD2 rs7122454: 5’-
ACG AAT TCT CCA TGT TAC T(C/G)-3’. In the cyclic iPLEX reaction the MassExtend 
primers were extended by a single base (Single Base Extension, SBE) that was 
complementary to the base at the polymorphic locus. These SBE products were then 
analyzed by MALDI-TOF mass spectrometry (Oeth et al., 2005). Thereby, the SNP 
genotype could be identified. 
Genotyping was successful in 98.1% of subjects for both investigated SNPs in the 
Munich sample. For the London sample Genotyping was successful in 97.1% of 
subjects for the rs1800497 SNP and 94.2% of subjects for the rs7122454 SNP. 
 
2.3 Startle Response Measurement 
The acoustic startle response (ASR) was measured with a commercially available 
electromyographic (EMG) startle reflex system (SR-Lab, San Diego, CA). The system 
generates and delivers the acoustic stimuli and, records and scores EMG activity for a 
period of 250 msec (sample interval = 1 msec) beginning at the onset of the acoustic 
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stimulus. The stimuli were presented binaurally to the subjects via headphones while 
they were sitting comfortably in a moderately lit laboratory room. The startle response 
was recorded from the right orbicularis oculi muscle with two (6 mm) silver/silver 
chloride electrodes filled with electrode gel. The electrodes were placed approximately 
1 cm below the pupil and 1 cm below the outer corner of the right eye. The ground 
electrode was located behind the left ear above the mastoid. Previously, the skin at 
these positions was cleaned with sterile alcohol swabs. 
Each session started with a 4-min acclimatization period consisting of 70dB white noise 
that was present throughout the session. Subjects were then presented with 49 white-
noise sound pulses. Each pulse-alone (PA) stimulus had an intensity of 110dB in the 
Munich sample and 115dB in the London sample which was presented for a period of 
40msec. The inter-trial intervals varied between 9 and 23sec (mean=15sec). In 36 of 
these trials, there was an 85-dB white noise prepulse presented for a period of 20msec 
preceding the pulse with a stimulus-onset asynchrony (SOA) of 30, 60 or 120msec (12 
trials for each SOA). The first PA trial was not used in the statistical analysis. The order 
of the remaining 48 trials was pseudo-randomized. The whole session lasted 
approximately 16 minutes. 
Each trial was inspected offline in order to exclude unusable trials, i.e. trials with 
unstable or noisy data. Scoring was performed by the analytic SR-Lab program. The 
criterion for the onset latency (msec) was a shift of 6 digital units from the baseline 
value occurring in a time window of 21–120msec after the pulse. The baseline was 
determined by the mean amplitude  (arbitrary analogue-to-digital units) in the first 
20msec after the pulse stimulus. The peak latency (msec) was defined as the point in 
time of maximal magnitude occurring within 150msec after the acoustic stimulus. 
Exclusion criteria for single trials were periods of more than 95msec between the onset 
and peak latencies, and onsets latency larger than 100msec. For all subjects the 
amplifier gain control was kept constant. A 50-Hz band-pass filter was applied to 
eliminate interference from the power mains. Subjects with response rejections > 30% 
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in PA trials were excluded from further analysis. Smoking before the assessment was 
not restricted to prevent effects of smoking withdrawal (Kumari et al., 1996). 
 
2.4 Statistical Analysis 
Statistical analysis using SPSS 17.0 (SPSS Inc., Chicago, IL) was identical in both 
samples. The significance level was set at p<.05. P-values between .1 and .05 were 
considered trends towards significance. In order to eliminate individual differences in 
startle responsivity, percent PPI was calculated as follows: 
( ) ( )
 trialalone-pulse of Amplitude
 trialprepulse of Amplitude trialalone-pulse of Amplitude100PPI% −⋅=
 
PPI was computed for 
each SOA and subject separately. Previous research has shown that gender (Aasen et 
al., 2005, Swerdlow et al., 1993) and smoking status (Swerdlow et al., 2006) influences 
PPI. Therefore, percent PPI was analyzed by analysis of covariance (ANCOVA) using 
the factors SOA and genotype of both SNPs and the covariates gender and smoking 
status.  
For the analysis of the habituation of the ASR, PA trials were divided into four blocks. 
Percent habituation was calculated as percent reduction in startle magnitude between 
the first and second block as well as between the first and last block of PA trials. Startle 
reactivity was measured by calculating the mean values of PA trials in the first block 
and across all four blocks. Moreover, the mean magnitudes of prepulse trials and 
latencies to onset and peak of the ASR in PA trials were analyzed. 
The analyses of genotype associations with demographic data and 
psychophysiological measures (habituation, startle reactivity and latency to onset) were 
conducted using one-way ANOVAs for continuous measures and Chi-square tests for 
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frequency data. Greenhouse-Geisser correction of degrees of freedom was applied to 
ANOVAs if the assumption of sphericity was violated as assessed by Mauchly’s test. 
On the basis of significant interactions post-hoc pairwise t-tests using Bonferroni 
correction were conducted. As the distribution of startle magnitudes significantly 
deviated from normal distribution a square root transformation was applied to normalize 
the data. It should be noted that the pattern of significant findings was independent of 
whether square root transformed or untransformed variables were used.  
To estimate effect sizes for between-group differences we used Cohen’s d. These 
calculations are based on pooled SOA conditions. To estimate effect sizes for 
differences between more than two groups partial eta-squared values were calculated 
(Pierce et al., 2004). 
Finally, in order to provide summary statistics of genotype associations across the two 
samples in this study, meta-analysis was carried out to assess genotype associations 
with PPI across both samples by using Stouffer's z-trend method and Fisher’s trend to 
combine p-values (Whitlock, 2005). For the analysis of effect sized across samples a 
random effects model was used according to Hedges and Olkin (1985). 
 
3. Results 
3.1 Munich sample 
Fifteen subjects were startle non-responders as defined by response rejections in more 
than 30% of PA trials and were excluded from further analysis, leaving a total sample 
of N=101.  
As expected, rs7122454 and rs4648317 were in complete LD (r²=1.0, d’=1.0). ANKK1 
Taq1A (rs1800497) and rs7122454/rs4648317 polymorphisms were not in strong LD 
(r²=0.01; d’=0.57). For ANKK1 Taq1A (χ²(1)=0.48; p=.49) and rs7122454/rs4648317 
VÖLTER ET AL. SENSORIMOTOR GATING AND D2 RECEPTOR SIGNALLING  13 
 
(χ²(1)=0.67; p=.41) genotype frequencies were distributed in accordance to the Hardy-
Weinberg Equilibrium (HWE). 
 
3.1.1 Genetic Associations with PPI 
Demographic and startle data of the Munich sample and their distribution across 
genotype groups are shown in Table 1 (for habituation and latency data see 
Supplementary Table S1). The ANKK1 Taq1A genotype groups differed in the gender 
distribution. However, startle magnitudes did not differ significantly between genotype 
groups. 
PPI was affected by genotype: a 3x2x2 (SOA condition x DRD2 rs7122454 SNP x 
ANKK1 Taq1A SNP) repeated measures ANCOVA with the covariates gender and 
smoking status revealed a significant main effect of SOA (F[2,190]=12.8; p<.001; 
partial η²=.12) and a trend-level effect of the covariate gender reflecting stronger PPI in 
males than females (F[1,95]=3.4; p=.07; partial η²=.04). Moreover, there was an 
interaction between SOA and ANKK1 Taq1A genotype (F[2,190]=5.9; p<.01; partial 
η²=.06) and a significant main effect of Taq1A genotype (F[1,95]=4.3; p<.05; partial 
η²=.04; d=.236), reflecting reduced PPI for A2A2 allele carriers compared to A1 allele 
carriers. In addition, there was a trend towards significance for rs7122454 (F[1,95]=3.5; 
p=.07; partial η²=.04; d=.660) pointing to lower PPI in CG/GG allele carriers compared 
to CC allele carriers. Finally, a significant interaction between the two SNPs was found 
(F[1,95]=5.3; p<.05; partial η²=.05) (see Fig 1). Bonferroni-corrected t-tests showed 
that subjects with the combination A2A2/rs7122454 G had significantly reduced PPI 
compared to A2A2/rs7122454 CC (p<.001; d=.872) and to A1/rs7122454 G (p<.05; 
d=.775) carriers. Furthermore, post-hoc tests on the basis of the significant interaction 
between SOA and ANKK1 Taq1A genotype revealed that A2A2 carriers had reduced 
PPI only at SOA 120msec (p<.01; d=.590) and by trend at SOA 60msec (p=.06; 
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d=.162). At SOA 30msec, there was no significant difference between the Taq1A 
genotype groups (p>.5). 
Finally, the effects of gender on the main effects of the two polymorphisms were 
investigated: when restricting the analysis to female subjects we observed a trend 
towards a main effect of Taq1A (F[1,65]=3.8; p=.056; d=.264; partial η²=.06) and a 
significant effect of rs7122454 (F[1,65]=4.5; p<.05; d=.726; partial η²=.06). In contrast, 
when analyzing only male subjects there was no significant association between PPI 
and Taq1A (F[1,26]=1.0; p=.32; d=.786; partial η²=.04) or rs7122454 (F[1,26]=0.2; 
p=.63; d=.562; partial η²=.01). 
3.2 London sample 
Four subjects were startle non-responders and excluded from further analysis, leaving 
a final sample of N=96. 
As expected, rs7122454 and rs4648317 were in complete LD (r²=1.0, d’=1.0). Again, 
ANKK1 Taq1A (rs1800497) and rs7122454/rs4648317 were in weak LD (r²=0.002; 
d’=0.30). For ANKK1 Taq1A (χ²(1)=0.12; p=.73) and rs7122454/rs4648317 (χ²(1)=0.06; 
p=.80) genotype frequencies were distributed in accordance to HWE. 
 
3.2.1 Genetic Associations with PPI 
Demographic and startle data of the London sample and their distribution across 
genotype groups are shown in Table 2 (for habituation and latency data see 
Supplementary Table S2). The DRD2 rs7122454 genotype groups differed in their 
gender distribution. However, startle magnitudes did not differ significantly between 
genotype groups. 
PPI was associated with one of the genotypes: a 3x2x2 (SOA condition x DRD2 
rs7122454 SNP x ANKK1 Taq1A SNP) repeated measures ANCOVA with the 
covariates gender and smoking status revealed a significant main effect of Taq1A 
VÖLTER ET AL. SENSORIMOTOR GATING AND D2 RECEPTOR SIGNALLING  15 
 
genotype (F[1,90]=7.2; p<.01; partial η²=.07; d=.752). This finding reflects reduced PPI 
for A2A2 allele carriers compared to A1 allele carriers (see Fig 2). In contrast, there 
was no effect of rs7122454 genotype (F[1,90]=0.6; p=.44; partial η²=.01; d=.002) or an 
interaction between the two SNPs (F[1,90]=0.1; p=.80; partial η²=.001). Additionally, 
there was the expected significant main effect of SOA (F[2,180]=7.7; p<.01; partial 
η²=.08). Finally, there was a significant effect of the covariate gender (F[1,90]=12.3; 
p<.01; partial η²=.12) indicating stronger PPI in males than females. 
Next, potential effects of gender on the Taq1A main effect were investigated: when 
restricting the analysis of the current data to female subjects we still observed a 
significant main effect of Taq1A (F[1,42]=4.6; p<.05; d=.704; partial η²=.06). In contrast, 
when analyzing only male subjects there was no significant association between PPI 
and Taq1A (F[1,44]=2.9; p=.10; d=.508; partial η²=.06). 
 
3.3 Meta-Analysis 
Meta-analysis across the two samples confirmed a significant effect of Taq1A (p<.01). 
Using the random effects model the combined effect size was d=.49. 
For rs7122454 the combined p-value was not statistically significant (p>.1). Using 
Fisher’s trend method the meta-analysis of the interaction between both investigated 
SNPs reveals a trend towards significance (p=.06) across samples.  
4. Discussion 
In the present study we aimed to investigate the relationship between sensorimotor 
gating and striatal D2 receptor signalling via two functional DRD2 related 
polymorphisms. Our results indicate an influence of DRD2 genotype on PPI: in the 
Munich sample both SNPs were associated with PPI. Considering the Taq1A SNP, the 
A2A2 allele status was associated with reduced PPI. This effect was replicated in the 
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London sample. With regard to rs7122454 (rs4648317), G (T) allele carriers showed 
reduced PPI in the initial sample. However, this effect was not confirmed by the data 
obtained from the London sample. Meta-analysis across both samples indicated a 
significant association of Taq1A but not of rs4648317/rs7122454 with PPI. In addition, 
we found a trend for an interaction between both SNPs across the two samples. 
Dopaminergic neurotransmission plays a major role within the striatum (e.g. Schultz, 
2002) and there is consistent evidence of striatal involvement in PPI modulation 
(review, Swerdlow et al., 2008). Some human pharmacological studies too, as noted 
earlier (Introduction), reveal the impact of striatal, dopaminergic neurotransmission on 
PPI (Abduljawad et al., 1998, 1999). In rats, increased dopaminergic 
neurotransmission in the NAC disrupts PPI via projections from the VP to the PPTg 
(Kretschmer and Koch, 1998). The present results are in line with these findings: the 
Taq1A A2A2 allele status that has previously been associated with increased striatal D2 
receptor availability (Jönsson et al., 1999, Pohjalainen et al., 1998a, Ritchie and Noble, 
2003, Thompson et al., 1997) shows an association with reduced PPI in our sample. 
The association of the Taq1A SNP with PPI is likely due to increased striatal D2 
receptor availability in A2A2 allele carriers compared to A1 allele carriers.  
The present findings can also be reconciled with evidence from dopaminergic disorders 
such as schizophrenia. Interestingly, it has been shown that in schizophrenia patients 
there is an increased baseline occupancy of striatal D2 receptors (Abi-Dargham et al., 
2000). Moreover, unaffected monozygotic twins of schizophrenia patients exhibit 
increased D2 receptor density in caudate compared with unaffected dizygotic twins and 
healthy controls (Hirvonen et al., 2005). Together with the current results, these 
findings suggest that increased striatal D2 dependent dopamine signalling might be at 
least partially responsible for PPI deficits in schizophrenia patients and their relatives. 
Future studies combining molecular imaging of striatal D2 receptor signalling, PPI 
recordings, and molecular genetics will allow to critically evaluate this hypothesis. 
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In the Munich sample, the association of Taq1A with PPI was present for the SOAs of 
60 and 120msec but not for 30msec. At longer SOAs attentional processes can 
modulate PPI (Filion et al., 1993). As these modulatory influences are not present at 
very short SOAs, D2 receptor dependent neurotransmission might not affect PPI at 
those SOAs which would explain the present findings. Earlier Kumari and colleagues 
(1999) had suggested a particularly strong influence of dopaminergic (D2) status on 
PPI at longer SOAs based on their data showing normal range 120-msec PPI in 
patients medicated with typical or atypical antipsychotics whereas only clozapine 
appeared to be effective at shorter SOAs.  
In contrast to the present results, Montag et al. (2008) and Roussos et al. (2008b) did 
not find associations of Taq1A SNP with PPI. The discrepancy of our findings and 
these previous results might be due to differences in the PPI measurement and sample 
characteristics: PPI was measured by Montag and colleagues using intensities of 
background noise, prepulse and pulse of 55dB, 74dB and 106dB, respectively. In 
contrast, in the current study, the intensity of background noise, prepulse and pulse 
was at 70, 85 and 110/115dB, respectively. We chose these parameters because of 
their proven sensitivity to schizophrenia in many previous studies (Kumari and Ettinger, 
2005). It has been already shown that stimulus characteristics (e.g. ambient 54 dB 
background noise versus experimentally delivered 70 dB background noise) 
dramatically alter PPI in healthy people (Hsieh et al., 2006) and can produce divergent 
results in comparisons of schizophrenia versus healthy populations (Braff et al., 2001). 
It is likely that stimulus characteristics are also a source of variance in genetic studies 
of human PPI. The sample of Roussos et al. included only young males and the startle 
paradigm used an experimental variation of the loudness of the prepulse. The two 
samples used in the current study were of mixed gender and demographically more 
heterogeneous. However, when we analyzed the gene effects for each gender 
separately we still found an association between Taq1A and PPI in female subjects. In 
contrast, no such effect was found in male subjects. This suggests that the association 
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found in the current study is mainly driven by female subjects which could explain the 
lack of an association of the Taq1A polymorphism with PPI in the Roussos study. It is 
likely that the absence of an association between Taq1A and PPI in the Munich sample 
is due to the small number of male subjects and to the interaction between gender and 
Taq1A genotype (the reasons for which are difficult to explain and currently unknown) 
yielding only very few male subjects with A1 genotype (N=3). However, in the London 
sample there are 18 male subjects with A1 genotype (and 15 female A1 subjects) and 
still there was no significant effect of Taq1A on PPI in male subjects. Whereas previous 
imaging studies on the effects of Taq1A on striatal D2 receptor signaling have not found 
gender differences (Jönsson et al., 1999, Pohjalainen et al., 1998a) the present results 
might be due to the generally lower striatal D2 receptor affinity found in women 
compared to men (Pohjalainen et al., 1998b). Higher D2 receptor affinity in men might 
mask the effects of Taq1A via changes in the D2 receptor density on PPI.  
Finally, on a descriptive level, Montag and colleagues (2008) also found lower levels of 
PPI for female A2A2 allele carriers compared to A1 carriers. 
Considering the second SNP investigated here, rs7122454 (rs4648317), the results of 
the Munich sample indicated that the G(T) allele status might be associated with 
reduced PPI. Previous research has shown that the G(T) allele status might also be 
related to increased nicotine dependence (Laucht et al., 2008). Laucht and colleagues 
suggested that this finding might rely on changes in striatal DRD2 expression which 
affects in turn the nicotine-induced reward. Interestingly, high levels of nicotine 
dependence have also been shown to disrupt PPI under smoking withdrawal (Kumari 
and Gray, 1999). The present relation might therefore be due to increased striatal D2 
receptor availability for the rs7122454 G/rs4648317 T genotype. However, since this 
effect could not be replicated in the London sample and imaging data are missing for 
this SNP, this conclusion remains speculative and requires further investigation. 
The differences in %PPI between the current samples require further discussion. Apart 
from population differences between London and Munich there are differences in 
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stimulus characteristics across samples: in the Munich sample we used a pulse 
intensity of 110 db, in contrast to 115db in the London sample. Recently, it has been 
shown that PPI magnitude is decreasing with increasingly intense pulse stimuli 
(Csomor et al., 2006, 2008, Yee et al., 2005). The current results confirm these 
findings: the mean %PPI level (across different SOAs) was significantly lower in the 
London sample (30.3%±17.6) than in the Munich sample (44.8%±21.1) (t[195]=5.2; 
p<.001). As already stated above such differences in stimulus characteristics are a 
source of additional variance that exacerbates the replication of genetic association 
studies. This additional variance might also be a reason for the failure to replicate the 
association between rs7122454 and PPI in the London sample. 
In summary, the present results indicate an association of DRD2 genotype with PPI in 
healthy humans. Specifically, increased striatal receptor availability as indicated by the 
Taq1A A2A2 genotype was associated with reduced PPI. This effect was replicated in 
a second, independent sample. However, the present findings must be considered 
within the broader context of previous studies, which did not find such an association. 
Overall, the molecular genetic approach may provide an important contribution to the 
characterization of the neural mechanisms of PPI by bridging the gap between 
evidence from pharmacological studies, imaging studies and molecular genetics. 
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Table 1. Demographic and psychophysiological data of the Munich sample grouped according to ANKK1 Taq1A and DRD2 rs7122454 
genotype.  
Legend: 
Mean values (±SD) are shown. Univariate ANOVAs (for %PPI: ANCOVA with gender and smoking status as covariates) and for the frequency data 
χ²-tests were computed revealing potential differences in the distribution of the shown variables between the genotype groups; * p < .05, (*)p<.1. 
 
ANKK1 Taq1A  A2A2 A1 Total ANKK1 Taq1A  
DRD2 
rs7122454 
ANKK1 Taq1A x  
DRD2 rs7122454 
DRD2 rs7122454 CC CG/GG CC CG/GG  F/χ² p F/χ² p F/χ² p df/dfer 
             
N 49(49%) 26(25%) 18(18%) 8(8%) 101(100%)        
Age, years  24.3±4.7 26.3±6.3 26.1±6.3 23.8±3.2 24.9±5.4 0.47 0.50 0.08 0.79 1.61 0.21 1/97 
Men, % 34.7 42.3 11.1 12.5 30.7 6.04 0.03* 0.51 0.50   1 
Smokers, % 8.0 3.8 11.1 0.0 6.9 0.04 1.00 1.23 0.42   1 
Years of Education 15.6 ±1.6 16.9±2.6 15.6±2.0 15.9±2.0 16.0±2.0 1.04 0.31 2.71 0.10 0.76 0.39 1/95 
First Block, Magnitude of 
PA Trials (Arbitrary Units) 
197.9± 
132.3 
214.2± 
129.3 
237.6±  
133.6 
263.2± 
189.8 
214.3± 
136.2 1.76 0.19 0.39 0.53 0.02 0.89 1/97 
Mean Magnitude of PA 
Trials (Arbitrary Units) 
143.3± 
101.8 
152.5± 
95.5 
180.8± 
107.1 
190.9±  
120.0 
156.2± 
102.5 2.20 0.14 0.10 0.75 0.00 0.95 1/97 
Mean Magnitude of PP30 
Trials (Arbitrary Units) 
99.4 ± 
81.7 
119.2 ± 
96.6 
145.1 ± 
99.5 
157.0 ± 
144.4 
117.2 ± 
95.4 2.82 0.10
(*) 0.26 0.61 0.17 0.69 1/97 
Mean Magnitude of PP60 
Trials (Arbitrary Units) 
57.1 ± 
40.2 
93.2 ± 
82.4 
86.7 ± 
74.4 
94.5 ± 
90.3 
74.6 ± 
65.4 0.73 0.39 1.64 0.20 1.25 0.27 1/97 
Mean Magnitude of PP120 
Trials (Arbitrary Units) 
49.9 ± 
43.8 
78.8 ± 
64.2 
53.6 ± 
59.1 
57.0 ± 
40.8 
58.6 ± 
53.0 0.49 0.49 2.13 0.15 0.69 0.41 1/97 
Mean %PPI across three 
SOA conditions 
50.4 ± 
14.4 
30.8 ± 
28.4 
47.9 ± 
17.4 
49.3 ± 
18.4 
44.8 ± 
21.1 4.29 0.04* 3.47 0.07
(*) 5.30 0.02* 1/95 
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Table 2. Demographic and psychophysiological data of the London sample grouped according to ANKK1 Taq1A and DRD2 rs7122454 
genotype. 
Legend: 
Mean values (±SD) are shown. Univariate ANOVAs (for PPI: ANCOVA with gender and smoking status as covariates) and for the frequency data 
χ²-tests were computed revealing potential differences in the distribution of the shown variables between the genotype groups; * p < .05. 
ANKK1 Taq1A  A2A2 A1 Total ANKK1 Taq1A  
DRD2 
rs7122454 
ANKK1 Taq1A x  
DRD2 rs7122454 
DRD2 rs7122454 CC CG/GG CC CG/GG  F/χ² p F/χ² p F/χ² p df/dfer 
             
N 48 (50%) 15 (16%) 27 (28%) 6 (6%) 96 (100%)        
Age, years  26.4±6.0 25.0±6.0 26.7±6.3 25.0±1.9 26.2±5.8 0.01 0.92 0.91 0.34 0.01 0.92 1/93 
Men, % 45.8 66.7 39.3 66.7 48.5 0.49 0.53 4.48 0.05*   1 
Smokers, % 16.7 33.3 33.3 33.3 25.0 2.29 0.14 0.46 0.56   1 
Years of Education 16.9±3.4 17.5±3.3 17.5±4.2 19.0±2.8 17.3±3.6 1.12 0.29 1.12 0.29 0.23 0.63 1/93 
First Block, Magnitude of 
PA Trials (Arbitrary Units) 
670.9± 
371.4 
876.2± 
523.1 
691.6± 
369.0 
583.3± 
273.1 
703.2± 
394.7 1.65 0.20 0.21 0.65 2.20 0.14 1/93 
Mean Magnitude of PA 
Trials (Arbitrary Units) 
528.2± 
346.2 
710.4±  
447.2 
584.6± 
353.9 
488.5± 
180.4 
570.2± 
359.4 0.23 0.64 0.24 0.63 1.27 0.26 1/93 
Mean Magnitude of PP30 
Trials (Arbitrary Units) 
472.9 ± 
332.2 
687.0 ± 
526.4 
484.1 ± 
322.9 
399.3 ± 
131.3 
495.3 ± 
352.1 0.97 0.33 0.37 0.55 1.29 0.26  1/93 
Mean Magnitude of PP60 
Trials (Arbitrary Units) 
343.6 ± 
218.1 
504.3 ± 
394.3 
322.2 ± 
226.3 
264.1 ± 
132.5 
350.0 ± 
247.1 2.62 0.11 0.31 0.58 1.61 0.21  1/93 
Mean Magnitude of PP120 
Trials (Arbitrary Units) 
288.8 ± 
202.8 
425.3 ± 
327.7 
312.1 ± 
249.0 
208.4 ± 
80.2 
303.4 ± 
224.5 1.71 0.19 0.06 0.80 2.15 0.15  1/93 
Mean %PPI across three 
SOA conditions 
26.2 ± 
19.3 
26.8 ± 
16.0 
38.0 ± 
13.2 
39.5 ± 
11.4 
30.4 ± 
17.6 7.24 0.01* 0.61 0.44 0.07 0.80 1/90 
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Titles and legends to figures  
Figure 1. The association of genotype with PPI in the Munich sample.  
Legend:  
Three different SOAs between prepulse and pulse were used: 30, 60 and 120msec. 
Mean PPI (+ SEM) across all participants of the Munich sample and grouped according 
to the DRD2 rs7122454 SNP / ANKK1 Taq1A genotype is depicted (post-hoc t-tests 
between genotype groups: *p < .05; ***p < .001; Bonferroni-corrected). Rs7122454 
genotype is shown nested within rs1800497 genotype groups. 
Figure 2. The association of genotype with PPI in the London sample.  
Legend: 
Three different SOAs between prepulse and pulse were used: 30, 60 and 120msec. 
Mean PPI (+ SEM) across all participants of the London sample and separated 
according to the DRD2 rs7122454 SNP / ANKK1 Taq1A genotype is shown. 
Rs7122454 genotype is shown nested withinTaq1A genotype groups. Taq1A 
A2A2 allele carrier exhibit significantly reduced PPI compared to A1 allele carriers (p < 
.01). 
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